Shares of Chimeric Therapeutics cratered 45.7% to A$0.02 on August 19, 2026, after the Australian cell therapy company resumed trading and revealed it had ceased enrolment in its flagship Phase 1 clinical trial — the one program investors were counting on to justify the company's existence.
The Only Drug That Mattered Just Hit a Wall. The trading halt was tied to pending results from Chimeric's CDH17 clinical trial, signaling potentially market-sensitive clinical data. That trial — a CAR-T cell therapy targeting advanced gastrointestinal cancers like colorectal, gastric, and neuroendocrine tumors — consumed roughly 60% of the company's total spending. Ceasing enrolment in a dose-escalation study, where the goal is to find the right dose to move forward, signals the program may have hit either a safety or efficacy barrier that makes further patient recruitment unjustifiable. For a company with no revenue and no approved products, losing its lead program is existential.
Promising Early Data Wasn't Enough. Just weeks earlier, the picture looked different. Preliminary findings from two patients at the highest dose showed tumor shrinkage of 17–40% in individual lesions and stable disease maintained for four to six months.
An earlier readout in May 2026 reported an 82% disease-control rate across 11 evaluable patients.
The therapy had also received FDA Orphan Drug and Fast Track designations during 2026 — regulatory boosts designed to speed development. Something evidently changed between those encouraging signals and the decision to stop enrolling.
Cash Was Already Running Out. Chimeric's most recent half-year report flagged a widened loss, an asset impairment charge, and going-concern risk — the accounting term for doubt about whether a company can stay afloat.
Management had already warned that enrolling the sixth and final patient depended on securing additional funding.
The board and executive team had taken pay cuts to cope with budget constraints. With a market capitalisation now likely in the low single-digit millions, raising fresh capital will be extraordinarily difficult.
What's Left in the Pipeline? Chimeric describes itself as having three CAR-T and NK cell assets in Phase 1 trials across multiple cancer types. But the CDH17 program was the clear centrepiece. Without it advancing, the remaining assets — an NK cell platform and a glioblastoma therapy — lack the clinical momentum to independently sustain investor confidence. At A$0.02, the market is pricing in near-total failure.